[ad_1]
Matthias Bodenstedt
Chief Monetary Officer
Welcome, everybody. Good morning, good afternoon. Thanks for becoming a member of at present’s webcast. My identify is Matthias Bodenstedt, I am the Chief Monetary Officer of MoonLake Immunotherapeutics. As standard, I am joined right here by our Co-Founder and CSO, Kristian Reich; our Co-Founder and CEO, Jorge da Silva. We’re additionally honored to be joined at present by Professor Alexa Kimball, a number one [indiscernible] in HS. We are going to undergo the information after which look ahead to the ideas and reflections of Professor Kimball on the VELA knowledge that we’ll be presenting at present. In the long run of the session, as standard, we’ll open up for Q&A.
Please be aware of our disclaimer on the forward-looking statements. [Operator Instructions]. The presentation doc and the replay of this presentation will likely be made obtainable on our IR web site on moonlaketx.com. With that, I am handing over to Jorge.
Jorge da Silva
Co-Founder, CEO & Director
Thanks, Matthias. Additionally from my aspect, welcome all. Good morning, good afternoon, relying on the place you might be. Thanks for making the time to affix our presentation at present.
I am going to begin very briefly with a fast abstract of the factors that we will be hitting within the name at present, most of which clearly has been lined within the press launch that was despatched out yesterday.
The principle messages are that clearly, the VELA-1 and VELA-2 trials fashioned the VELA program, which, as you recognize, has been testing sonelokimab in adults with reasonable to extreme HS to a main endpoint readout at week 16. Importantly, from a regulatory perspective, and clearly, for
[ad_2]
